PALO ALTO, Calif.--(BUSINESS WIRE)--Cancer Commons, an initiative of CollabRx, a provider of information technology to personalize cancer treatments and accelerate research, announces the publication of a first-of-its-kind molecular disease model of melanoma (MDMM) which classifies the disease into molecular subtypes, rather than traditional histological or cellular subtypes, and describes treatment guidelines for each subtype, including specific assays, drugs, and clinical trials. The paper, titled “Molecular Disease Model for Melanoma,” by Vidwans et al, was published in the March 30th issue of PLoS ONE [link].
